Aripiprazole Tablet
Product Images NDC 63629-7774

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 63629-7774). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C103b8f2-figure-01 (Aripiprazole Tablets 1)

FDA Label Image

Fig-1 (Aripiprazole Tablets 2)

This text seems to be a table showing the effect of certain drugs on aripiprazole, including their CYP inhibitors, gastric acid blockers, and other drugs, as well as the fold change and 90% CI of aripiprazole. It is difficult to interpret the table without additional information or context.*

FDA Label Image

Fig-2 (Aripiprazole Tablets 3)

This is a list of drugs and their possible effects on aripiprazole, a medication used to treat schizophrenia and bipolar disorder. The list includes drugs that may inhibit or induce the activity of enzymes in the liver (CYpas) that are involved in the metabolism of aripiprazole, as well as drugs that may affect gastric acid levels. The provided image shows a graph displaying the fold change and percentage of change relative to a reference value without the interacting drugs.*

FDA Label Image

Fig-3 (Aripiprazole Tablets 4)

This text provides information on the effect of aripiprazole on other drugs, specifically on their metabolic pathways. The CYP2D6 B enzyme and drugs such as dextromethorphan, warfarin, omeprazole, and escitalopram are mentioned, as well as UGT1A4 and other drugs. The text also includes a fold change and 90% I graph showing the change relative to the reference without interacting drugs. No further information is available.*

FDA Label Image

Fig-4 (Aripiprazole Tablets 5)

This appears to be a table showing various factors that can impact the pharmacokinetics (PK) of a drug, such as age, gender, hepatic impairment, and renal impairment. It also shows the Avipiprazole Fold Change and 90% CI, which may be relevant for drug development and dosing calculations.*

FDA Label Image

Fig-5 (Aripiprazole Tablets 6)

This is a report on patient demographics including gender, age, and medical conditions such as Hepatic and Renal impairments. Additionally, there is a chart showing the Denyaro-Aripiprazole Fold Change and 90% CI relative to a reference value.*

FDA Label Image

Fig-6 (Aripiprazole Tablets 7)

This appears to be a graph showing a comparison of the relapse rate between two groups - one taking Avipiprazole and the other taking a placebo. The x-axis represents the days from randomization and the y-axis represents the proportion with relapse. However, the graph is not readable as some of the characters are missing or distorted, especially in the y-axis.*

FDA Label Image

01 (Aripiprazole Tablets 8)

FDA Label Image

0102 (Aripiprazole Tablets 9)

This text appears to show a clinical trial comparing the effects of the drug Aripiprazole with a placebo in preventing relapse in a group of subjects. The data is presented in a graph, showing a proportion of subjects experiencing relapse over time, as well as a table of the number of subjects at risk in each group. The text provides no further details on the trial, outcome measures or populations, and is not sufficient to draw any definitive conclusions about the efficacy of Aripiprazole.*

FDA Label Image

Label Image (Lbl636297774)

This is a packaging label for Abilify 30mg Tablet by Amneal Pharmaceuticals. It includes information such as the expiration date, NDC number, and storage instructions. The label also reminds users to keep all drugs out of reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.